Xenetic Biosciences reports Q2 2021 net loss of $1.1M; completes $12.5M private placement

Xenetic Biosciences, Inc.

2022-Q2 EPS reported -$0.28 revenue$478,819

Net loss $1.1M for Q2 2021; cash $9.3M at quarter end.
R&D expenses rose 70.4% to $0.5M, driven by XCART spending.
Received ~$0.3M in royalty payments from Takeda sublicense in Q2.
Completed $12.5M private placement in August 2021, net proceeds ~$11.4M.
Advancing XCART personalized CAR T platform toward IND-enabling studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.